| Regimen Comparison | Relative Risk (95% CI) | Source, Year (Reference) | ||
|---|---|---|---|---|
| Pneumocystis carinii Pneumonia | Cerebral Toxoplasmosis | Mortality Outcomes | ||
| Any primary prophylaxis vs. placebo | 0.39 (0.27-0.55) | Not reported | 0.87 (0.60-1.25) | Ioannidis, et al., 1996a,b 194 |
| Trimethoprim-sulfamethoxazole vs. aerosolized pentamidine | 0.59 (0.45-0.76) | 0.78 (0.55-1.11) | 0.88 (0.74-1.06) | Bucher, et al., 1997a 195 |
| 0.58 (0.45-0.75) | Not reported | 0.99 (0.80-1.22) | Ioannidis, et al., 1996a,b 194 | |
| Dapsone-based regimen vs. aerosolized pentamidine | 0.90 (0.71-1.15) | 0.72 (0.54-0.97) | 1.07 (0.90-1.27) | Bucher, et al., 1997a 195 |
| 0.93 (0.72-1.19) | Not reported | 0.98 (0.86-1.12) | Ioannidis, et al., 1996a,b 194 | |
| Trimethoprim-sulfamethoxazole vs. dapsone-based regimen | 0.49 (0.26-0.92) | 1.17 (0.68-2.18) | 1.08 (0.88-1.25) | Bucher, et al., 1997a 195 |
| 0.61 (0.34-1.10) | Not reported | 0.95 (0.82-1.11) | Ioannidis, et al., 1996a,b 194 | |
| Atovaquone vs. dapsone | 0.81 (0.58-1.12) | 1.18 (0.26-5.30) | 1.25 (0.98-1.59) | El-Sadr, et al., 1998196 |
| Dapsone vs. pyrimethamine-sulfadoxine | 0.87 (P > 0.05) | 1.07 (P > 0.05) | 1.15 (not significant) | Payen, et al., 1997197 |
| Azithromycin vs. rifabutin in patients already receiving P. carinii prophylaxis | 0.42 (0.24-0.76) | Not reported | Not reported | Dunne, et al., 1999198 |
Notes: aSystematic review.
bIncludes studies of secondary prophylaxis.